ERBB2 and breast cancer: For example, ultra-deep sequencing of a breast cancer sample identified sub-clones with mutations conferring Lapatinib (HER2 (Human Epidermal Growth Factor Receptor 2) inhibitor) resistance, indicating that an alternative treatment (Trastuzumab) may be more appropriate to reduce the risk of drug resistance and disease recurrence [118].